Explore a selection of our essential drug information below, or:
Identification
- Summary
Hesperidin is a bioflavonoid found in a variety of nutritional supplements that is touted to have various beneficial effects on blood vessel disorders and various other conditions.
- Generic Name
- Hesperidin
- DrugBank Accession Number
- DB04703
- Background
Hesperidin is a flavan-on glycoside found in citrus fruits.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Hesperidin (DB04703)
- Weight
- Average: 610.5606
Monoisotopic: 610.189770418 - Chemical Formula
- C28H34O15
- Synonyms
- (S)-(−)-hesperidin
- Cirantin
- Ciratin
- Hesperetin 7-O-rutinoside
- Hesperidin
- Hesperidina
- Hesperidoside
- External IDs
- NDI 590
- NSC-44184
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to manage Capillary fragility Combination Product in combination with: Diosmin (DB08995) •••••••••••• •••••• Used in combination to manage Venous insufficiency Combination Product in combination with: Diosmin (DB08995) •••••••••••• •••••• Symptomatic treatment of Varicosities •••••••••••• •••••••• ••••••••••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism AVoltage-dependent N-type calcium channel subunit alpha-1B inhibitorHumans UAurora kinase B regulatorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image AVEFLON TABLET Hesperidin (50 mg) + Diosmin (450 mg) Tablet, film coated Oral APEX PHARMACY MARKETING SDN. BHD. 2020-09-08 Not applicable Malaysia 
Cilobana Cpa Tab Hesperidin (75 mg / tab) + Ascorbic acid (150 mg / tab) + Bromelains (4 mg / tab) + Citrus bioflavonoids (75 mg / tab) + Vitamin A (10000 unit / tab) Tablet Oral Anabolic Laboratories Inc. 1968-12-31 1996-10-02 Canada 
Daflon 1000mg Film-Coated Tablet Hesperidin (100 mg) + Diosmin (900 mg) Tablet, film coated Oral SERVIER MALAYSIA SDN. BHD. 2020-09-08 Not applicable Malaysia Daflon 500 mg - Filmtabletten Hesperidin (50 mg) + Diosmin (450 mg) Tablet, film coated Oral Servier Austria Gmb H 1994-11-18 Not applicable Austria 
daflon 500mg tablets Hesperidin (50 mg) + Diosmin (450 mg) Tablet, film coated Oral SERVIER MALAYSIA SDN. BHD. 2020-09-08 Not applicable Malaysia
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as flavonoid-7-o-glycosides. These are phenolic compounds containing a flavonoid moiety which is O-glycosidically linked to carbohydrate moiety at the C7-position.
- Kingdom
- Organic compounds
- Super Class
- Phenylpropanoids and polyketides
- Class
- Flavonoids
- Sub Class
- Flavonoid glycosides
- Direct Parent
- Flavonoid-7-O-glycosides
- Alternative Parents
- 4'-O-methylated flavonoids / 3'-hydroxyflavonoids / 5-hydroxyflavonoids / Flavanones / Phenolic glycosides / O-glycosyl compounds / Disaccharides / Chromones / Methoxyphenols / Phenoxy compounds show 14 more
- Substituents
- 1-benzopyran / 1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / 3'-hydroxyflavonoid / 4p-methoxyflavonoid-skeleton / 5-hydroxyflavonoid / Acetal / Alcohol / Alkyl aryl ether / Anisole show 33 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- rutinoside, disaccharide derivative, 3'-hydroxyflavanones, monomethoxyflavanone, flavanone glycoside, dihydroxyflavanone (CHEBI:28775) / flavanones (C09755)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- E750O06Y6O
- CAS number
- 520-26-3
- InChI Key
- QUQPHWDTPGMPEX-QJBIFVCTSA-N
- InChI
- InChI=1S/C28H34O15/c1-10-21(32)23(34)25(36)27(40-10)39-9-19-22(33)24(35)26(37)28(43-19)41-12-6-14(30)20-15(31)8-17(42-18(20)7-12)11-3-4-16(38-2)13(29)5-11/h3-7,10,17,19,21-30,32-37H,8-9H2,1-2H3/t10-,17-,19+,21-,22+,23+,24-,25+,26+,27+,28+/m0/s1
- IUPAC Name
- (2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-({[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-3,4-dihydro-2H-1-benzopyran-4-one
- SMILES
- COC1=CC=C(C=C1O)[C@@H]1CC(=O)C2=C(O1)C=C(O[C@@H]1O[C@H](CO[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@@H](O)[C@H](O)[C@H]1O)C=C2O
References
- Synthesis Reference
Hiromi Hijiya, Toshio Miyake, ".alpha.-glycosyl hesperidin, and its preparation and uses." U.S. Patent US5652124, issued June, 1983.
US5652124- General References
- Not Available
- External Links
- KEGG Drug
- D01038
- KEGG Compound
- C09755
- PubChem Compound
- 10621
- PubChem Substance
- 46506898
- ChemSpider
- 10176
- BindingDB
- 61776
- 5281
- ChEBI
- 28775
- ChEMBL
- CHEMBL449317
- ZINC
- ZINC000008143568
- PharmGKB
- PA449867
- PDBe Ligand
- H1N
- Wikipedia
- Hesperidin
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Active Not Recruiting Basic Science Leg edema / Varicose Veins of Lower Limb / Varix / Vascular Diseases 1 somestatus stop reason just information to hide Not Available Completed Not Available Internal Haemorrhoids 1 somestatus stop reason just information to hide Not Available Completed Basic Science Varicosities of the great saphenous vein 1 somestatus stop reason just information to hide 4 Completed Treatment Lymphedema Lower Extremity 1 somestatus stop reason just information to hide 4 Completed Treatment Venous Insufficiency 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Powder Oral 100.00 mg Tablet, film coated Oral Suspension Oral 1000 mg Tablet, sugar coated Oral Tablet, coated Oral Tablet, delayed release Oral Tablet Oral 900.000 mg Suspension Oral Tablet, coated Oral 500 mg Tablet, film coated Tablet, extended release Oral Capsule, liquid filled Oral 500 mg Tablet, film coated Oral 450 mg Tablet Oral Capsule Oral Tablet Oral 450.000 mg Powder, for suspension Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 2.69 mg/mL ALOGPS logP -0.27 ALOGPS logP -0.31 Chemaxon logS -2.4 ALOGPS pKa (Strongest Acidic) 8.61 Chemaxon pKa (Strongest Basic) -3.6 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 15 Chemaxon Hydrogen Donor Count 8 Chemaxon Polar Surface Area 234.29 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 140.77 m3·mol-1 Chemaxon Polarizability 58.87 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 255.8648737 predictedDarkChem Lite v0.1.0 [M-H]- 247.5912737 predictedDarkChem Lite v0.1.0 [M-H]- 222.63536 predictedDeepCCS 1.0 (2019) [M+H]+ 255.2088737 predictedDarkChem Lite v0.1.0 [M+H]+ 247.5176737 predictedDarkChem Lite v0.1.0 [M+H]+ 224.53075 predictedDeepCCS 1.0 (2019) [M+Na]+ 255.4858737 predictedDarkChem Lite v0.1.0 [M+Na]+ 230.43336 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. This alpha-1B subunit gives rise to N-type calcium currents. N-type calcium channels belong to the 'high-voltage activated' (HVA) group. They are involved in pain signaling. Calcium channels containing alpha-1B subunit may play a role in directed migration of immature neurons. Mediates Ca(2+) release probability at hippocampal neuronal soma and synaptic terminals (By similarity)
- Specific Function
- Amyloid-beta binding
- Gene Name
- CACNA1B
- Uniprot ID
- Q00975
- Uniprot Name
- Voltage-dependent N-type calcium channel subunit alpha-1B
- Molecular Weight
- 262493.84 Da
References
- Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Regulator
- General Function
- Serine/threonine-protein kinase component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis (PubMed:11516652, PubMed:12925766, PubMed:14610074, PubMed:14722118, PubMed:29449677). The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly (PubMed:11516652, PubMed:12925766, PubMed:14610074, PubMed:14722118, PubMed:26829474). Involved in the bipolar attachment of spindle microtubules to kinetochores and is a key regulator for the onset of cytokinesis during mitosis (PubMed:15249581). Required for central/midzone spindle assembly and cleavage furrow formation (PubMed:12458200, PubMed:12686604). Key component of the cytokinesis checkpoint, a process required to delay abscission to prevent both premature resolution of intercellular chromosome bridges and accumulation of DNA damage: phosphorylates CHMP4C, leading to retain abscission-competent VPS4 (VPS4A and/or VPS4B) at the midbody ring until abscission checkpoint signaling is terminated at late cytokinesis (PubMed:22422861, PubMed:24814515). AURKB phosphorylates the CPC complex subunits BIRC5/survivin, CDCA8/borealin and INCENP (PubMed:11516652, PubMed:12925766, PubMed:14610074). Phosphorylation of INCENP leads to increased AURKB activity (PubMed:11516652, PubMed:12925766, PubMed:14610074). Other known AURKB substrates involved in centromeric functions and mitosis are CENPA, DES/desmin, GPAF, KIF2C, NSUN2, RACGAP1, SEPTIN1, VIM/vimentin, HASPIN, and histone H3 (PubMed:11756469, PubMed:11784863, PubMed:11856369, PubMed:12689593, PubMed:14602875, PubMed:16103226, PubMed:21658950). A positive feedback loop involving HASPIN and AURKB contributes to localization of CPC to centromeres (PubMed:21658950). Phosphorylation of VIM controls vimentin filament segregation in cytokinetic process, whereas histone H3 is phosphorylated at 'Ser-10' and 'Ser-28' during mitosis (H3S10ph and H3S28ph, respectively) (PubMed:11784863, PubMed:11856369). AURKB is also required for kinetochore localization of BUB1 and SGO1 (PubMed:15020684, PubMed:17617734). Phosphorylation of p53/TP53 negatively regulates its transcriptional activity (PubMed:20959462). Key regulator of active promoters in resting B- and T-lymphocytes: acts by mediating phosphorylation of H3S28ph at active promoters in resting B-cells, inhibiting RNF2/RING1B-mediated ubiquitination of histone H2A and enhancing binding and activity of the USP16 deubiquitinase at transcribed genes (By similarity). Acts as an inhibitor of CGAS during mitosis: catalyzes phosphorylation of the N-terminus of CGAS during the G2-M transition, blocking CGAS liquid phase separation and activation, and thereby preventing CGAS-induced autoimmunity (PubMed:33542149). Phosphorylates KRT5 during anaphase and telophase (By similarity). Phosphorylates ATXN10 which promotes phosphorylation of ATXN10 by PLK1 and may play a role in the regulation of cytokinesis and stimulating the proteasomal degradation of ATXN10 (PubMed:25666058)
- Specific Function
- Atp binding
- Gene Name
- AURKB
- Uniprot ID
- Q96GD4
- Uniprot Name
- Aurora kinase B
- Molecular Weight
- 39310.195 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
- de Groot CO, Hsia JE, Anzola JV, Motamedi A, Yoon M, Wong YL, Jenkins D, Lee HJ, Martinez MB, Davis RL, Gahman TC, Desai A, Shiau AK: A Cell Biologist's Field Guide to Aurora Kinase Inhibitors. Front Oncol. 2015 Dec 21;5:285. doi: 10.3389/fonc.2015.00285. eCollection 2015. [Article]
Drug created at September 11, 2007 17:49 / Updated at August 26, 2024 19:24